Clinical Trial Update: Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 study evaluating 3-V Bioscience-2640 to reduce de novo lipogenesis in adults with metabolic syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• 3-V Bioscience-2640

Snippet

Sponsor: University of Missouri-Columbia | Conditions: Metabolic Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-04-20